|
|
|
| Study on Characteristics of EGFR Gene Mutation in Patients with Different Pathological Types of Lung Adenocarcinoma |
| ZHOU Rui-qing, YANG Rui-qing, LIU Bin, et al |
| Fuyang Peoples Hospital, Anhui Province 236000 |
|
|
|
|
Abstract 【Objective】 To investigate the characteristics of epidermal growth factor receptor (EGFR) gene mutation in patients with different pathological types of lung adenocarcinoma. 【Methods】 A total of 286 patients with lung adenocarcinoma were retrospectively analyzed. Basic information of patients (gender, age, nationality, smoking history, drinking history, family history, blood type, tumor location, clinical stage, degree of differentiation, lymph node metastasis) were counted and compared. The mutants of EGFR gene were detected to show the characteristics of EGFR gene mutation in patients with different pathological types.【Results】 Test results showed that among 286 cases of lung adenocarcinoma, 152 patients had EGFR gene mutation mainly with E19 and E21 mutations, accounting for 40.79% and 39.47%, respectively. The proportion of EGFR gene-positive women, Han nationality, no smoking history, clinical stage Ⅲ or Ⅳ, and well-differentiated patients was significantly higher than that of men, ethnic minorities, smoking history, clinical stage Ⅰ or Ⅱ, and poorly differentiated patients (P<0.05) .There were significant differences in EGFR gene positivity among patients with different pathological types in the new classification (P<0.05).In semi-quantitative comprehensive classification, the positive pathological types of EGFR gene were not mainly adherent and acinar-based, instead nipple and variant-containing types were significantly more than EGFR negative patients (P<0.05).There was no significant difference in the proportion of positive and negative EGFR in WHO pathological types (P>0.05). 【Conclusion】 The mutation of EGFR gene in lung adenocarcinoma is more common in women, Han nationality, non-smoking history, clinical stage Ⅲ or Ⅳ, highly differentiated patients, and there are differences in the incidence of EGFR gene mutations in patients with different pathological types in the new classification criteria of lung adenocarcinoma.
|
|
Received: 31 July 2019
|
|
|
|
|
|
[1] 谢世超. 晚期肺癌患者D-二聚体水平及其临床意义[J].临床肺科杂志, 2016, 21(4):632-634.
[2] 蒋伟, 奚俊杰, 徐松涛,等. 不同病理分型对Ⅰ期肺腺癌预后的影响[J].中华外科杂志, 2015, 53(10):737-741.
[3] 黄其文, 姜汉国. 胸腔积液细胞块切片免疫组化染色技术鉴别诊断肺腺癌的临床研究[J].临床肺科杂志, 2017, 22(2):227-229.
[4] 单姗, 王艺朵, 任涛. LB100对EGFR基因突变的肺腺癌细胞吉非替尼获得性耐药的逆转作用[J].中华医学杂志, 2016, 96(42):3398-3402.
[5] 乐胜兵, 吴密璐. 非小细胞肺癌靶向治疗研究进展[J].现代肿瘤医学, 2016, 24(5):840-843.
[6] 张萍, 聂鑫, 李旭,等. 老年晚期肺腺癌患者表皮生长因子受体基因突变及临床特征分析[J].中华老年医学杂志, 2018, 37(2):171-174.
[7] 张著学, 彭学勤, 薛英波, 等. 肺腺癌中表皮生长因子受体基因突变与临床病理因素的关系[J].实用医学杂志, 2015,31(13):2155-2157.
[8] 单莉, 张琰, 赵峰, 等. 维吾尔族肺腺癌患者的EGFR基因突变分析[J].中国肺癌杂志, 2013,16(2):78-81.
[9] Dacic S, Shuai Y, Yousem S, et al. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas[J].Mod Pathol,2010, 23(2):159-168.
[10] Yoshizawa A , Sumiyoshi S , Sonobe M , et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients[J].J Thorac Oncol,2013, 8(1):52-61. |
|
|
|
2020, Vol. 37 
